Table 2.
Demographic, Clinical, and Treatment Characteristics for Patients Who were Eligible and Started Treatment
| Characteristic | Overall (n = 35) n (%) | Arm A (n = 17) n (%) | Arm B (n = 18) n (%) |
| Age, years | |||
| Median (range) | 60 (46–76) | 64 (49–76) | 59 (46–74) |
| ECOG Performance Status | |||
| 0 | 23 (66) | 12 (71) | 11 (61) |
| 1 | 12 (34) | 5 (29) | 7 (39) |
| Prior Anti-VEGF Agent | |||
| Bevacizumab | 15 (43) | 5 (29) | 10 (56) |
| Pazopanib | 11 (31) | 6 (35) | 5 (28) |
| Sorafenib | 4 (11) | 2 (12) | 2 (11) |
| Sunitinib | 5 (14) | 4 (24) | 1 (6) |
| Time from Last Anti-VEGF Treatment, days | |||
| Median (range) | 28 (10–76) | 26 (10–44) | 29 (13–76) |
| # greater than 30 days | 14 (40) | 6 (35) | 8 (44) |
| Number of Prior Regimens | |||
| Median (range) | 3 (1–8) | 3 (1–6) | 3 (1–8) |
| Gender | |||
| Female | 8 (23) | 4 (24) | 4 (22) |
| Male | 27 (77) | 13 (76) | 14 (78) |
| Race/Ethnicity | |||
| American Indian/AlaskaNative | 2 (6) | 2 (12) | 0 |
| Asian/Pacific Islander | 1 (3) | 0 | 1 (6) |
| Black | 3 (9) | 2 (12) | 1 (6) |
| Hispanic | 8 (23) | 4 (24) | 4 (22) |
| White | 21 (60) | 9 (53) | 12 (67) |